Identification of a novel starfish neuropeptide that acts as a muscle relaxant

Chan-Hee Kim,† Eun Jung Kim,* † Hye-Jin Go,* Hye Young Oh,* Ming Lin,† Maurice R. Elphick† and Nam Gyu Park*

†Department of Biotechnology, College of Fisheries Sciences, Pukyong National University, Busan, Korea
‡School of Biological and Chemical Sciences, Queen Mary University of London, London, UK

Abstract

Neuropeptides that act as muscle relaxants have been identified in chordates and protostomian invertebrates but little is known about the molecular identity of neuropeptides that act as muscle relaxants in deuterostomian invertebrates (e.g. echinoderms) that are evolutionary intermediates of chordates and protostomes. Here, we have used the apical muscle of the starfish Patiria pectinifera to assay for myorelaxants in extracts of this species. A hexadecapeptide with the amino acid sequence Phe-Gly-Lys-Gly-Gly-Ala-Tyr-Asp-Pro-Leu-Ser-Ala-Gly-Phe-Thr-Asp was identified and designated starfish myorelaxant peptide (SMP). Cloning and sequencing of a cDNA encoding the SMP precursor protein revealed that it comprises 12 copies of SMP as well as 3 peptides (7 copies in total) that are structurally related to SMP. Analysis of the expression of SMP precursor transcripts in P. pectinifera using qPCR revealed the highest expression in the radial nerve cords and lower expression levels in a range of neuromuscular tissues, including the apical muscle, tube feet and cardiac stomach. Consistent with these findings, SMP also caused relaxation of tube foot and cardiac stomach preparations. Furthermore, SMP caused relaxation of apical muscle preparations from another starfish species – Asterias amurensis. Collectively, these data indicate that SMP has a general physiological role as a muscle relaxant in starfish. Interestingly, comparison of the sequence of the SMP precursor with known neuropeptide precursors revealed that SMP belongs to a bilaterian family of neuropeptides that include molluscan pedal peptides (PP) and arthropodan orcokinins (OK). This is the first study to determine the function of a PP/OK-type peptide in a deuterostome.

Keywords: muscle, neuropeptide, orcokinin, pedal peptide, relaxation, starfish.

J. Neurochem. (2016) 137, 33–45.
neuromuscular preparations from et al. (1999; Elphick and Melarange 2001; Melarange and Garcia-Arraras 1995; Ohtani 2002). In vitro pharmacological tests with S1 and S2 revealed that both peptides cause relaxation of neuromuscular preparations from A. rubens – the cardiac stomach, tube feet and apical muscle – but with S2 more potent/effective than S1 (Elphick et al. 1995; Melarange et al. 1999; Elphick and Melarange 2001; Melarange and Elphick 2003). Subsequently, other members of the SALMFamide neuropeptide family were identified in other echinoderms (e.g. sea cucumbers) and these peptides were also found to act as muscle relaxants (Diaz-Miranda and Garcia-Arraras 1995; Ohtani et al. 2002).

It is unlikely that SALMFamides are the only family of neuropeptides that act as muscle relaxants in echinoderms, given the multitude of neuropeptides that have been found to act as muscle relaxants in vertebrates and protostomian invertebrates (see above). Therefore, here we set out to employ use of an in vitro muscle bioassay to screen for muscle relaxants in an echinoderm. The starfish species *P. pectinifera* was selected as a model system because it is widely distributed in the northern Pacific Ocean, and can be easily collected and transported as it is found in shallow coastal waters. This species adapts well to artificial conditions with respect to the vertebrates and protostomes in animal phylogeny – the deuterostomian invertebrates, which include two chordate subphyla that are closely related to vertebrates (Urochordata and Cephalochordata) and the Ambulacraria (Hemichordata and Echinodermata) (Adoutte et al. 2000).

Nothing is known about the molecular identity of neuropeptides that act as muscle relaxants in hemichordates but neuropeptides that act as muscle relaxants have been identified in echinoderms – the SALMFamides. The prototypes for this family of neuropeptides were both identified in the starfish *Asterias rubens* and *Asterias forbesi* – S1 (GFNSALMF-NH₂) and S2 (SGPYSFNSGLTFT-NH₂) (Elphick et al. 1991a,b). In vitro pharmacological tests with S1 and S2 revealed that both peptides cause relaxation of neuromuscular preparations from *A. rubens* – the cardiac stomach, tube feet and apical muscle – but with S2 more potent/effective than S1 (Elphick et al. 1995; Melarange et al. 1999; Elphick and Melarange 2001; Melarange and Elphick 2003). Subsequently, other members of the SALMFamide neuropeptide family were identified in other echinoderms (e.g. sea cucumbers) and these peptides were also found to act as muscle relaxants (Diaz-Miranda and Garcia-Arraras 1995; Ohtani et al. 2002).

To purify the starfish myorelaxant peptide (SMP), A. rubens was selected as a bioassay model system because it can be easily dissected from the aboral body wall because it can be easily dissected from the aboral body wall. The boiled sample was cooled on ice and then homogenized (PT10-35; Kinematics AG, Luzern, Switzerland), followed by addition of glacial acetic acid to yield a final concentration of 5% acetic acid. The homogenate was then centrifuged (10,000 g, 40 min, 4°C). The pellet was re-extracted in 5% acetic acid with same extraction method. The supernatant was pooled and concentrated using a rotary evaporator. The concentrated solution was diluted with 10 volumes of ethanol and then the suspension was centrifuged (10,000 g, 40 min, 4°C) to remove the precipitate. The supernatant was evaporated to 100 mL, and then 100 mL of ethanol with 1.1 g sodium chloride was added to it. After centrifugation to remove precipitate, the supernatant was concentrated by evaporation, and 0.1 volume of 1 N hydrochloric acid was added. The precipitate was removed again by centrifugation (20,000 g, 50 min, 4°C) and the supernatant was applied to a C18 cartridge (Sep-pak C18; Waters Corp., Milford, Massachusetts, USA). The column was washed with 10% methanol/0.1% trifluoroacetic acid (TFA) and retained materials were then eluted with 60% methanol/0.1% TFA. The eluate was evaporated and its biological activity on the apical muscle of *P. pectinifera* was investigated, as described below in the methods section for *in vitro* bioassay and pharmacology.

**Methods**

**Animals**

Live specimens of the starfish species *P. pectinifera* (Fig. 1a and b) and *Asterias amurensis* were collected at Cheongsapo of Busan, Korea, and maintained in a recirculating seawater system at 15°C until use. The animals were fed once every 3 days with live manila clam, *Ruditapes philippinarum*. Live specimens of the starfish species *Asterias rubens* were collected at low tide from the Thanet coast of Kent in the UK, and maintained in a recirculating seawater system at 12°C until use. The animals were fed weekly with live mussels (*Mytilus edulis*). Approval by the local institution/ethics committee was not required for this work because experimental work on starfish is not subject to regulation.

**Peptide extraction**

Starfish (*P. pectinifera*) were cut into pieces using scissors, soaked in 70% methanol and then heated in a double boiler for 5 min to denature proteins and inhibit proteolytic enzyme activity. The boiled sample was cooled on ice and then homogenized (PT10-35; Kinematica AG, Luzern, Switzerland), followed by addition of glacial acetic acid to yield a final concentration of 5% acetic acid. The homogenate was then centrifuged (10,000 g, 40 min, 4°C). The pellet was re-extracted in 5% acetic acid with same extraction method. The supernatant was pooled and concentrated using a rotary evaporator. The concentrated solution was diluted with 10 volumes of ethanol and then the suspension was centrifuged (10,000 g, 40 min, 4°C) to remove the precipitate. The supernatant was evaporated to 100 mL, and then 100 mL of ethanol with 1.1 g sodium chloride was added to it. After centrifugation to remove precipitate, the supernatant was concentrated by evaporation, and 0.1 volume of 1 N hydrochloric acid was added. The precipitate was removed again by centrifugation (20,000 g, 50 min, 4°C) and the supernatant was applied to a C18 cartridge (Sep-pak C18; Waters Corp., Milford, Massachusetts, USA). The column was washed with 10% methanol/0.1% trifluoroacetic acid (TFA) and retained materials were then eluted with 60% methanol/0.1% TFA. The eluate was evaporated and its biological activity on the apical muscle of *P. pectinifera* was investigated, as described below in the methods section for *in vitro* bioassay and pharmacology.

**Peptide purification**

The 60% methanol eluate was applied to a cation-exchange column (CM-S2, 2.5 x 30 cm; Whatman, Maidstone, UK), and eluted with a linear gradient of 0.02–1.5 M ammonium acetate (pH 5.0) for 6 h at a flow rate of 2.75 mL/min. Absorbance peaks were monitored at 254 nm (ISCO Model UA-6 detector; Lincoln, NE, USA) and fractions were collected every 4 min. The bioactive fractions, which eluted between fraction numbers 40–45, were pooled and then subjected to reversed phase (RP)-HPLC (Vydac 218TP510 Protein & Peptide C18, 9.2 x 250 mm; The Separation Group, Inc., Hesperia, CA, USA). Elution was performed with a
linear gradient of 0–60% acetonitrile/0.1% TFA at a flow rate of 3.0 mL/min for 120 min, and fractions were collected every 2 min. Bioactive fractions eluted between 50 and 54 min with RP-HPLC and these were subjected to further purification steps using an anion-exchange column (TSKgel DEAE-5PW, 7.5 x 75 mm; Tosho Corp., Minato-ku, Tokyo, Japan) with a linear gradient of 0–0.5 M sodium chloride in 10 mM Tris-HCl (pH 9.2) at a flow rate of 0.5 mL/min for 100 min. A fraction that eluted with a concentration of about 0.1 M sodium chloride from the anion-exchange column caused relaxation of the apical muscle from *P. pectinifera*. This eluate was subjected to further RP-HPLC (Capcellpak C18, 4.6 x 250 mm; Shisheido CO. LTD., Chuo-ku, Tokyo, Japan). The absorbance peaks were recovered with a linear gradient of 15–30% acetonitrile/0.1% TFA at flow rate of 1 mL/min for 60 min. The bioactive peak was then subjected again to RP-HPLC using the same solvent gradient as in the previous RP-HPLC step but with a different column (Hypersil-BDS C18, 2 x 125 mm; HP, Waldbronn, Germany). Finally, the active peak was applied to the same column as in the previous step but with an isotropic elution of 20% acetonitrile/0.1% TFA at a flow rate of 0.5 mL/min.

Structure determination and synthesis of peptides

To determine the molecular mass and amino acid sequence of the purified SMP, it was analysed using an automated N-terminal amino acid gas-phase sequencer (PPSQ-1; Shimadzu Corp. Nakagyo-ku, Kyoto, Japan) and a MALDI-TOF mass spectrometer (Voyager-DE™ PRO spectrometer; Perseptive Biosystem, Framingham, MA, USA). On the basis of the structural determination results, two peptides, with or without the carboxyl-terminus amidated, were automatically synthesized by a conventional solid-phase method with Fmoc-protected amino acids and coupling reagents, 1-hydroxybenzotriazole and N,N-diisopropylcarbodiimide, using a peptide synthesizer (PSSM-8; Shimadzu) as described previously (Kim et al. 2015). Other neuropeptides, S1 (GFNSALMFamide), S2 (SGPYSFNsGLTFamide), FMRFamide and FLRFamide were synthesized to enable comparison of their activities with that of the identified peptide.

In vitro bioassay and pharmacology

Three neuromuscular preparations, apical muscle, cardiac stomach and tube feet, were dissected from *P. pectinifera* for *in vitro* bioassay and pharmacology according to a slightly modified version of previously reported methods (Elphick et al. 1995; Melarange and Elphick 2003). Synthetic neuropeptides were also tested for bioactivity on apical muscle preparations from a different starfish species – *A. amurensis*. Briefly, the apical muscle was cut from the aboral body wall of an arm, where the apical muscle forms a thickening of longitudinally orientated muscle that runs along the mid-line of the inner side (Fig. 1c). A piece of cardiac stomach between the oral opening and extrinsic retractor strand was obtained by removing the aboral body wall from the central disc and the proximal region. An individual whole tube foot was dissected from the arm ambulacra but without the ampulla. All muscle preparations were cut to approximately 10 mm, and both ends of the muscle preparations were tied with cotton threads. The preparations were then suspended vertically in a 2 mL polypropylene chamber containing artificial seawater (ASW) with aeration, one end being connected to silver hook on the bottom of the chamber and the other to a force displacement...
transducer (Type 45196A; NEC-Sanei Instrument Ltd., Tokyo, Japan). Output from the force displacement transducer was monitored by a recorder (WR7300; GRAPHTEC CORP., Yokohama, Japan) via an amplifier (AS1302; NEC-Sanei Instrument Ltd.), which recorded the mechanical responses of the device. Prior to testing, the muscle preparations were allowed to stabilize for about 90 min. The resting tension was then adjusted to 1.0 g for apical muscle and 0.5 g for cardiac stomach and tube foot. Muscles in the chamber were allowed to equilibrate for about 30 min in ASW, during which time the ASW in the chamber was freshly replaced every 15 min. Pre-contraction of apical muscle, cardiac stomach or tube foot preparations was induced by applying 1 µM acetylcholine (ACh), 10 µM carbacol or 30 mM high-potassium ASW respectively. Then immediately after equilibration, the muscles were treated with test samples to measure relaxation responses.

The bioassay system adopted for monitoring purification of the bioactive peptide was a system that measures relaxation of apical muscle from *P. pectinifera* pre-contraction for 2 min at 20 min intervals with 1 µM ACh. An aliquot of each test fraction was evaporated to dryness, dissolved with 50 µL of phosphate-buffered saline, and added into the chamber.

At least four separate experiments to test the pharmacological activities of synthetic SMP, C-terminally amidated SMP (SMPa) and other neuroneptides were performed, using a concentration range of 10⁻¹⁰ M to 10⁻⁵ M at 25°C. EC₅₀ values represent the concentration of peptide required to cause a response 50% of the maximum. The maximal response (Eₘₐₓ) was expressed as the percentage of the maximal relaxation induced by 10⁻⁴ or 10⁻⁶ M of each peptide compared to the maximal contraction of apical muscle by 1 µM ACh, of cardiac stomach by 10 µM carbacol or of tube foot by 30 mM high-potassium ASW. The relative activity was calculated as the ratio of the concentration of SMP or other peptides required to produce responses equivalent to a half-maximal response.

cDNA cloning and sequence analysis

Total RNA was extracted using RNeasy Mini kit (Qiagen, Valencia, CA, USA) from total tissues (except body wall) of *P. pectinifera*, and then mRNA was purified using Oligotex mRNA mini kit (Qiagen) following the manufacturer’s instructions. The synthesis rapid amplification cDNA end (RACE)-ready cDNA template was performed with SMARTer® RACE cDNA amplification Kit (Clontech, Mountain view, CA, USA) according to manufacturer’s instructions.

Based on the amino acid sequence of the purified peptide, two degenerate primers were designed for 3’ RACE PCR, and then 5’ RACE PCRs were conducted with sequence-specific primers designed from the sequencing result of the 3’ RACE product. The sequences of primers used in RACE are listed in Table S1. The first PCR conditions for 3’ RACE included initial denaturation at 94°C for 3 min followed by: 5 cycles of 94°C for 1 min, 59°C for 1 min and 72°C for 1 min; 5 cycles of 94°C for 1 min, 57°C for 1 min and 72°C for 1 min; 20 cycles of 94°C for 1 min, 55°C for 1 min and 72°C for 1 min. Nested PCR for 3’ RACE was performed with the same conditions as the first PCR. The first PCR product of 5’ RACE was obtained by the following thermal cycle profile: 5 cycles of 94°C for 30 s, 67°C for 30 s and 72°C for 1 min; 5 cycles of 94°C for 30 s, 65°C for 30 s and 72°C for 1 min; 25 cycles of 94°C for 30 s, 63°C for 30 s and 72°C for 1 min. Nested PCR for 5’ RACE was as follows: 5 cycles of 94°C for 30 s, 69°C for 30 s and 72°C for 1 min; 5 cycles of 94°C for 30 s, 67°C for 30 s and 72°C for 1 min; 25 cycles of 94°C for 30 s, 65°C for 30 s and 72°C for 1 min. PCR products in the last step of 3’ and 5’ RACE were introduced into the pGEM-Teasy vector system (Promega, Madison, WI, USA) and sequenced. The full-length translated sequence of the SMP precursor, based on the cloned cDNA nucleotide sequence, was aligned by BLAST (http://blast.ncbi.nlm.nih.gov/blast.cgi) and the sequence was submitted to the GenBank database (Accession number: KT870152). Multiple sequence alignment of the full-length *P. pectinifera* SMP precursor and related proteins in other species was performed using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/).

* Asterias rubens* radial nerve cord transcriptome sequence data obtained by Illumina HiSeq sequencing, as reported previously (Semmens et al. 2013), were analysed using BLAST to identify a homologue of the *P. pectinifera* SMP precursor. Using the sequence of the *P. pectinifera* SMP precursor as a query, a 444 bp *A. rubens* contig (1025452) comprising a partial sequence corresponding to the 3’ region of the *P. pectinifera* SMP precursor cDNA was identified. Then ovarian transcriptome sequence data obtained from multiple echinoderm species [(Reich et al. 2015); http://www.echinobase.org/Echinobase/Blasts] was analysed and non-overlapping contigs encoding the 5’ region (GAUS01027726.1) and the 3’ region (GAUS01027727.1) of a SMP-type precursor transcript was identified from the starfish species *Asterias forbesi*. Combining these partial sequence data from *A. rubens* and *A. forbesi*, primers were designed to enable PCR amplification of the full-length SMP precursor coding sequence from *A. rubens*, as described below.

Total RNA was extracted from radial nerve cords of *A. rubens* using the SV Total RNA Isolation System according to the manufacturer’s instructions (Promega). Then cDNA was synthesized using the QuantiTect Rev. Transcription Kit in accordance with the manufacturer’s instructions (Qiagen). A cDNA containing the coding sequence of the *A. rubens* SMP-type precursor was amplified by PCR using Phusion high-fidelity PCR master mix (NEB, Ipswich, MA, USA) and the oligo primers 5’-ATGCCGGCT-CATCATGCA3’-3’ and 5’-TACACCAAAGCAGTGACA-3’. The conditions for PCR included initial denaturation at 98°C for 2 min followed by: 30 cycles of 98°C for 10 s, 55°C for 30 s, 72°C for 1 min, 72°C for 8 min and hold at 4°C. 1% gel electrophoresis was performed to analyze the PCR products and then the PCR product was gel-extracted and purified using a QIAquick gel extraction kit (Qiagen). Zero Blunt TOPO PCR cloning kit (Invitrogen, Carlsbad, CA, USA) was used to ligate the PCR product into the pCR-Blunt II with TOPO vector for sequencing. The sequence obtained (GenBank accession number KT870153) was translated into protein sequence using ExPaSy (http://web.expasy.org/translate/) and SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/) was used to predict the signal peptide of the translated protein sequence.

**Real-time quantitative PCR (RT-qPCR) analysis**

To quantitatively analyse expression of SMP precursor transcripts in different starfish tissues/organs, RT-qPCR was employed using a LightCycler 480 Real-Time PCR System (Roche, Mannheim, Germany) with LightCycler 480 SYBR green master I (Roche). Total RNA extracted from the apical muscle, radial nerve cord, cardiac stomach, pyloric stomach, coelomic lining containing...
transverse muscles, tube feet, pyloric caeca, testis and ovary were obtained from five specimens of *P. pectinifera*. cDNA was synthesized using the TOPscript cDNA synthesis Kit with oligo dT (dT18) (Enzymonics, Daejeon, Korea) according to the manufacturer’s instructions. The primer pairs used for amplifying SMP precursor cDNA and elongation factor 1α (EF1α) cDNA as a control for normalization were SMP RT-F and SMP RT-R, and EF1α RT-F and EF1α RT-R respectively (see Table S1 for sequences). Based on the standard curves for both SMP and EF1α, the relative expression levels of SMP transcripts in each tissue were normalized against the level of the EF1α control using the following formula: relative expression = ((1 + E_{SMP})^{CP}_{SMP})^{-1}/((1 + E_{EF1α})^{CP}_{EF1α})^{-1}, in which E is PCR efficiency (E = 10^{-1/slope} – 1) and CP is the threshold cycle number. Triplicate amplifications were carried out independently, and the relative quantification results were expressed as the fold levels of SMP precursor transcripts.

Statistical analysis
All data are presented as means ± standard deviation. The statistical analysis for pharmacological data were performed using two-way analysis of variance (ANOVA) supported by Bonferroni’s multiple comparisons test when carrying out pair wise comparison between the same doses of different peptides. For RT-qPCR data, comparison between tissues was carried out by one-way ANOVA, followed by Duncan’s Multiple Range test.

Statistical analyses were performed using spss 21 program (SPSS, Chicago, IL, USA) and graphs were generated using GraphPad Prism software version 6.0 for Windows (GraphPad Software, San Diego, CA, USA). p values with p < 0.05 were considered statistically significant.

Results
Purification of a novel hexadecapeptide that relaxes the apical muscle of *P. pectinifera*
A whole-body extract of *P. pectinifera* induced relaxation of apical muscle pre-contracted with ACh (Fig. 1d), indicating that it was an appropriate source to isolate myorelaxants. A single absorbance peak (peak A) containing a myorelaxant was successfully purified from the whole-body extract through six steps of column purification which sequentially were cation, repeated RP and anion HPLC. Finally, peak A was isocratically eluted with 20% acetonitrile/0.1% TFA at 16.1 min of the retention time (Fig. 2a). An aliquot of peak A was isolated and sequenced (GenBank accession number: KT870152) and predicted by SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP), a N-terminal spacer peptide (Ser20-Arg56) containing several acidic amino acids, a region containing twelve copies of SMP and seven copies of other SMP-like peptides copy bounded by dibasic cleavage sites (Phe57-Arg402) and a C-terminal region (Thr403-Arg426). The synthetic SMP precursor encodes a 426 amino acid residue protein that contains four regions: a signal peptide (Met1-Ala19), as predicted by SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP), a N-terminal spacer peptide (Ser20-Arg56) containing several acidic amino acids, a region containing twelve copies of SMP and seven copies of SMP-like peptides with each peptide copy bounded by dibasic cleavage sites (Phe57-Arg426) and a C-terminal region (Thr403-Arg426).

The *P. pectinifera* SMP precursor protein comprises twelve copies of SMP and seven copies of other SMP-like peptides A cDNA encoding the *P. pectinifera* SMP precursor was cloned and sequenced (GenBank accession number: KT870152) and the nucleotide sequence and the deduced protein sequence are shown in Fig. 3. The cDNA sequence comprised 1682 bp, starting with a 5′ untranslated region of 148 bp, followed by an open reading frame of 1281 bp, a 3′ untranslated region of 253 bp including a poly-A tail. The open reading frame of the SMP precursor encodes a 426 amino acid residue protein that contains four regions: a signal peptide (Met1-Ala19), as predicted by SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP), a N-terminal spacer peptide (Ser20-Arg56) containing several acidic amino acids, a region containing twelve copies of SMP and seven copies of SMP-like peptides with each peptide copy bounded by dibasic cleavage sites (Phe57-Arg426) and a C-terminal region (Thr403-Arg426).

SMP precursor transcripts are widely expressed in *P. pectinifera* and SMP causes in vitro relaxation of other muscle preparations from *P. pectinifera*
The relative expression levels of the SMP precursor mRNA in different tissues (apical muscle, radial nerve cord, cardiac...
stomach, pyloric stomach, coelomic lining, tube feet, pyloric caecae, testis and ovary) were determined by RT-qPCR (Fig. 4a). The highest expression of SMP precursor transcripts was detected in radial nerve cords, which are the major components of the nervous system in starfish. In addition, relatively high expression levels of SMP precursor transcripts were observed, in descending order, in apical muscle, tube feet, coelomic lining, cardiac stomach, pyloric stomach and pyloric caecae. However, the expression of SMP precursor transcripts in reproductive organs (ovary and testis) was barely detectable. These findings indicate that SMP is a neuropeptide and suggest that SMP may have widespread roles as a regulator of muscle activity in P. pectinifera. To address this issue, SMP was tested in vitro on two other neuromuscular preparations in which SMP precursor transcripts are detected – cardiac stomach and tube feet. SMP caused dose-dependent relaxation of both preparations and, as with apical muscle preparations, SMP was more potent/effective as a muscle relaxant than the SALMFamides S1 and S2 (Fig. 4b and c).

**SMP causes relaxation of apical muscle preparations from the starfish Asterias amurensis and identification of an SMP-type precursor in Asterias rubens**

Having identified SMP as a muscle relaxant in *P. pectinifera*, we then investigated if this peptide also acts as a muscle relaxant in other starfish species. To address this issue we tested synthetic SMP on apical muscle preparations from *A. amurensis*. SMP caused dose-dependent relaxation and the $E_{\text{max}}$ was 82.1 ± 1.94% at a concentration of $10^{-5}$ M (Fig. 5a). Previous studies have shown that the SALMFamide neuropeptides S1 and S2 cause relaxation of apical muscle by 1 µM ACh (e). Representative recording of the concentration-dependent relaxing effect of SMP on *P. pectinifera* apical muscle pre-contracted with 1 µM ACh (f).
Fig. 3 Precursor of starfish myorelaxant peptide (SMP) in Patina pectinifera. The DNA sequence of a transcript (lowercase, 1682 bases) encoding the P. pectinifera SMP precursor (uppercase, 426 amino acid residues) is shown. The predicted signal peptide, the purified mature SMP (SMPa) and three other variants (SMPb, [Met3]-SMPa; SMPc, [Met3, Glu16]-SMPa; SMPd, SMPa-related octadecapeptide) are shown in blue, red, pink, orange and purple, respectively, and putative dibasic cleavage sites (KR) are shown in green. The asterisk shows the position of the stop codon. The SMP precursor protein comprises twelve copies of SMP and seven copies of SMP-like peptides.

Fig. 4 The expression levels for the starfish myorelaxant peptide (SMP) precursor transcript in various organs/tissues from P. pectinifera and the pharmacological effects of SMP on cardiac stomach and tube foot from P. pectinifera. Relative expression levels of SMP transcripts in each organ/tissue were normalized against the level of the EF1α gene as an internal control. Mean ± standard deviation (n = 3) are shown. Means denoted by the same letter did not differ significantly (p > 0.05) whilst different letters (a, b, c, d, e) at the top of the bars indicate statistically significant differences (p < 0.05) between tissues determined by one-way ANOVA followed by Duncan’s Multiple Range test (a). SMP caused concentration-dependent relaxation of the cardiac stomach (b) and tube foot (c) from P. pectinifera. The relaxing activity of SMP (●) was compared with S1 (▲) and S2 (▲). Each point represents the mean ± standard deviation determined from four separate experiments. Statistically significant difference between SMP and S1/S2 represents with ****p < 0.0001. The percentage relaxing activity was calculated by comparing each relaxation effect to the maximal contraction of cardiac stomach caused by 10–8 M carbacol and of tube foot caused by 30 mM high-potassium artificial seawater respectively. Representative recordings of the effects of SMP on cardiac stomach (d) and tube foot (e) preparations are shown.
Therefore, we compared the bioactivity of SMP with S1 and A. amurensis related to C0 of 10-4. Therefore, we compared the bioactivity of SMP with S1 and S2, and S1 and S2 are represented by black, red and blue asterisks. The concentration-dependent relaxing activity of SMP (●) compared with S1 (▲) and S2 (▼) on the apical muscle of A. amurensis. Each point represents the mean ± standard deviation determined from four separate experiments. Statistically significant differences between the effects of SMP and S1, SMP and S2, and S1 and S2 are represented by black, red and blue asterisks (*p < 0.05, **p < 0.001 and ***p < 0.0001), respectively. The percentage relaxing activity was calculated by comparing each relaxation effect to the maximal contraction of apical muscle caused by 1 μM ACh.

Fig. 5 Pharmacological effect of starfish myorelaxant peptide (SMP) on apical muscle from Asterias amurensis and identification of an SMP-type precursor in Asterias rubens. (a). The concentration-dependent relaxing activity of SMP (●) compared with S1 (▲) and S2 (▼) on the apical muscle of A. amurensis. Each point represents the mean ± standard deviation determined from four separate experiments. Statistically significant differences between the effects of SMP and S1, SMP and S2, and S1 and S2 are represented by black, red and blue asterisks (*p < 0.05, **p < 0.001 and ***p < 0.0001), respectively. The percentage relaxing activity was calculated by comparing each relaxation effect to the maximal contraction of apical muscle caused by 1 μM ACh. (b) Amino acid sequence of a 224-residue SMP-type precursor protein identified in 3. rubens, which comprises a predicted 20-residue signal peptide (blue) and eight copies of putative SMP-like peptides (red) and putative dibasic cleavage sites (KR, green). The sequence of the cDNA encoding this protein is shown in Figure S2.

Discussion

Here, we have isolated a novel hexadecapeptide (FGKGGAYDPLSAGFTD) from starfish that acts as a muscle relaxant and which we have designated as SMP. Previous studies have identified the SALMFamide neuropeptides S1 and S2 as muscle relaxants in starfish (Melerange et al. 1999, Melarange and Elphick 2003) and here the bioactivity of SMP, S1 and S2 as muscle relaxants were compared. When tested on three preparations from P. pectinifera (apical muscle, cardiac stomach and tube feet), SMP was more effective/potent than S1 or S2. This finding is likely to be physiologically relevant with respect to S1 because we know that S1 occurs in the closely related species Patiria miniata. However, P. miniata does not contain S2 and this species has instead an S2-like peptide (Elphick et al. 2013, 2015). Therefore, the inferior bioactivity of S2 as a myorelaxant in P. pectinifera may in part be attributable to

Starfish SMP precursors are homologues of neuropeptide precursors that have been identified in other echinoderms. To investigate relationships with neuropeptide precursors that have been in other animals, the P. pectinifera and A. rubens SMP precursor proteins were submitted as queries against the GenBank nr database using BLAST. The top two hits (XP_785647.1 and XP_003727926) were identified as neuropeptide precursor proteins that have been described previously from the sea urchin Stronglylocentrotus purpuratus and designated as Spnp6 and Spnp7, respectively (Rowe and Elphick 2012). In Fig. 6, we show a multiple sequence alignment of the P. pectinifera SMP precursor, the A. rubens SMP-type precursor, Spnp6, Spnp7 and a homologue of Spnp7 that has been identified in the sea cucumber Apostichopus japonicus [Ajn7 (Rowe et al. 2014)]. Furthermore, alignment of the putative neuropeptides derived from the P. pectinifera SMP precursor, the A. rubens SMP-type precursor, Spnp6, Spnp7 and Ajn7 (Fig. 7) reveals that the peptides have a number of features in common. These include two phenylalanine residues located at or near the N- and C-termini of the peptides as well as a conserved core region with the motif (D/E)-(P)-(L/M), structural characteristics that may be important for the bioactivity of these peptides.

Fig. 5a Graph representing the pharmacological effect of starfish myorelaxant peptide (SMP) on apical muscle from Asterias amurensis and identification of an SMP-type precursor in Asterias rubens. (a) The concentration-dependent relaxing activity of SMP (●) compared with S1 (▲) and S2 (▼) on the apical muscle of A. amurensis. Each point represents the mean ± standard deviation determined from four separate experiments. Statistically significant differences between the effects of SMP and S1, SMP and S2, and S1 and S2 are represented by black, red and blue asterisks (*p < 0.05, **p < 0.001 and ***p < 0.0001), respectively. The percentage relaxing activity was calculated by comparing each relaxation effect to the maximal contraction of apical muscle caused by 1 μM ACh. (b) Amino acid sequence of a 224-residue SMP-type precursor protein identified in A. rubens, which comprises a predicted 20-residue signal peptide (blue) and eight copies of putative SMP-like peptides (red) and putative dibasic cleavage sites (KR, green). The sequence of the cDNA encoding this protein is shown in Figure S2.

Discussion

Here, we have isolated a novel hexadecapeptide (FGKGGAYDPLSAGFTD) from starfish that acts as a muscle relaxant and which we have designated as SMP. Previous studies have identified the SALMFamide neuropeptides S1 and S2 as muscle relaxants in starfish (Melerange et al. 1999; Melarange and Elphick 2003) and here the bioactivity of SMP, S1 and S2 as muscle relaxants were compared. When tested on three preparations from P. pectinifera (apical muscle, cardiac stomach and tube feet), SMP was more effective/potent than S1 or S2. This finding is likely to be physiologically relevant with respect to S1 because we know that S1 occurs in the closely related species Patiria miniata. However, P. miniata does not contain S2 and this species has instead an S2-like peptide (Elphick et al. 2013, 2015). Therefore, the inferior bioactivity of S2 as a myorelaxant in P. pectinifera may in part be attributable to
differences in peptide structure. Furthermore, analysis of the sequences of the two SALMFamide precursor proteins in *P. miniata* reveals that they comprise S1, the S2-like peptide and fourteen other SALMFamide-type peptides (Elphick et al. 2013, 2015). So comparison of the effects of SMP with S1 or S2 tested in isolation does not reflect the physiological occurrence of ‘cocktails’ of SALMFamides. Nevertheless, the superior bioactivity of SMP as a myorelaxant, compared to S1 and S2, in tests on muscle preparations from both *P. pectinifera* and *Asterias amurensis* clearly indicates that SMP is a physiologically important regulator of muscle relaxation in starfish.

Analysis of the distribution of the expression of the SMP precursor in *P. pectinifera* using qPCR revealed that they comprise S1, the S2-like peptide and fourteen other SALMFamide-type peptides (Elphick et al. 2013, 2015). So comparison of the effects of SMP with S1 or S2 tested in isolation does not reflect the physiological occurrence of ‘cocktails’ of SALMFamides. Nevertheless, the superior bioactivity of SMP as a myorelaxant, compared to S1 and S2, in tests on muscle preparations from both *P. pectinifera* and *Asterias amurensis* clearly indicates that SMP is a physiologically important regulator of muscle relaxation in starfish.

Analysis of the distribution of the expression of the SMP precursor in *P. pectinifera* using qPCR revealed a widespread pattern of expression, including all three neuromuscular preparations that SMP causes relaxation of in vitro – the apical muscle, cardiac stomach and tube feet. Likewise, immunocytochemical- and radioimmunoassay-based analysis of the distribution of S1 and S2 in *A. rubens* reveals a widespread pattern of expression (Moore and Thorndyke 1993; Elphick et al. 1995; Newman et al. 1995a,b). Therefore, it is likely that SMP and SALMFamide neuropeptides act in concert as muscle relaxants to regulate a variety of physiological processes in starfish. For example, relaxing effects on the apical muscle *in vivo* may be associated with neural mechanisms that control changes in body posture, whereas relaxing effects on tube feet *in vivo* may be associated with locomotor activity. The relaxing action of SALMFamides on the cardiac stomach is thought to be relevant to neural mechanisms controlling stomach eversion during feeding in starfish (Melarange et al. 1999) and this role may equally apply to the novel SMP neuropeptide identified here. Further insights into the physiological roles of SMP and other SMP-like peptides derived from the same precursor protein may be obtained by analysis of the distribution of these peptides at the cellular level. As highlighted above, detailed immunocytochemical analyses of the distribution of S1 and S2 in *A. rubens* have been reported previously (Moore and Thorndyke 1993; Elphick et al. 1995; Newman et al. 1995a,b) and it would be interesting to compare the distribution of SMP and SALMFamides using this approach.

Comparative analysis of the sequence of SMP and the SMP precursor with neuropeptides and neuropeptide precursors that have been identified in other animals reveals that SMP belongs to a bilaterian family of neuropeptides that includes molluscan pedal peptides (PP) and arthropodan orckinins (OK) (Fig. 8, Figure S3 and Table S2). The sequences of Spnp6, Spnp7 and Ajnp7 are from (Rowe and Elphick 2012; Rowe et al. 2014).
reported previously based on analysis of genome/transcriptome sequence data (Rowe and Elphick 2012; Rowe et al. 2014) and in Figs 6 and 7, respectively, we show alignments of SMP and the SMP precursor with related PP/OK-type neuropeptides and precursor proteins that have been identified in the sea urchin *S. purpuratus* and the sea cucumber *A. japonicus*. Conserved residues are highlighted in black and grey.

Fig. 7 Alignment of starfish myorelaxant peptide (SMP) with putative SMP-like neuropeptides derived from echinoderm SMP-type precursors: the starfish *P. pectinifera* and *A. rubens*; sea urchin *S. purpuratus*; sea cucumber *A. japonicus*. Conserved residues are highlighted in black and grey.

Fig. 8 Alignment of echinoderm starfish myorelaxant peptide (SMP)-type peptides with protostomian pedal peptide (PP)/orcokinin(OK)-type peptides. The basic amino acids Lys, Arg and His are shown in the black with light grey highlighting, and the acidic residues Glu and Asp are shown in black with dark grey highlighting. All other amino acids are classified as hydrophobic (white with light grey highlighting) or hydrophilic (white with dark grey highlighting). Lower case ‘a’ denotes a C-terminal amide group. Species abbreviations and references: Pp, *P. pectinifera*; Ar, *A. rubens*; Sp, *S. purpuratus* (Reich et al. 2015); Aj, *A. japonicus* (Du et al. 2012; Rowe and Elphick 2012); Ac, *Aplysia californica* (Moroz et al. 2006); Pd, *Platynereis dumerilii* (Conzelmann et al. 2011); Ce, *Caenorhabditis elegans* (Nathoo et al. 2001); Pc, *Procambarus clarkii* (Yasuda-Kamatani and Yasuda 2000); Nv, *Nasonia vitripennis* (Hauser et al. 2010).

© 2016 The Authors. *Journal of Neurochemistry* published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Novel starfish myorelaxant neuropeptide

A. japonicus. These alignments reveal conserved residues that may be important for the bioactivity of PP/OK-type peptides in echinoderms. In Fig. 8 we show an alignment of SMP and other representative echinoderm PP/OK-type peptides with molluscan pedal peptides and arthropod orcokinins. What this reveals is the conservation of hydrophobic residues, which are typically phenylalanine, proximal to or at the N- and C-termini of the peptides. This suggests that these evolutionarily conserved structural features are important for the bioactivity of PP/OK-type peptides in the Bilateria. However, the motif (D/E)-(P)-(L/M) that is a conserved feature of the core of echinoderm PP/OK-type peptides, including SMP (Fig. 7), is not seen in molluscan and arthropod PP/OK-type peptides and therefore this may be a unique characteristic of echinoderm representatives of this neuropeptide family. Investigation of the structure-activity relationships of orcokinin in Orectonectes limosus has revealed that C-terminal amidation results in a reduction of bioactivity (Bungart et al. 1995), whereas here we found that C-terminal amidation of SMP neither reduces nor enhances its bioactivity. These findings contrast with neuropeptides that are naturally C-terminally amidated in vivo, where loss of the C-terminal amide typically results in a dramatic loss of bioactivity (Greenberg and Price 1979).

With the identification of SMP as a member of the PP/OK-type family of neuropeptides, it is of interest to consider what is known about the physiological roles of these neuropeptides in other phyla. PP was originally discovered in the mollusc Aplysia californica as a peptide that causes contraction of pedal muscles (Lloyd and Connolly 1989; Hall and Lloyd 1990); it also stimulates beating of cilia associated with the foot (Longley and Peterman 1993). OK was isolated from neural extracts of the crayfish Orectonectus limosus in 1980 by Stangier et al. (1992). Subsequently, OK-type peptides have been identified in several arthropod species and found to have a variety of effects, including stimulation of the prothoracic gland and regulation of ecdysteroidogenesis in the silk moth Bombyx mori (Yamanaka et al. 2011) and regulation of circadian activity in the cockroach Leucophaea maderae (Hofer and Homberg 2006; Soehlet et al. 2011; Wei and Stengl 2011). Thus, in both molluscs and arthropods, PP/OK-type neuropeptides have stimulatory effects on the activity of muscle and other tissues. This contrasts with the inhibitory effect that SMP has in causing relaxation of muscle in starfish, as reported here. It will be interesting, therefore, to investigate in future studies if PP/OK-type peptides also act as muscle relaxants in other echinoderms or if this is a unique characteristic of PP/OK-type peptides in starfish.

Thus far, PP/OK-type peptides have not been identified in other deuterostomian phyla such as hemichordates, which are a sister clade to the echinoderms, or chordates. One possibility is that PP/OK-type peptides have been lost in hemichordates and chordates and the echinoderms are unique amongst the deuterostomes in retaining peptides belonging to this bilaterian neuropeptide family. Alternatively, the possibility remains that members of this neuropeptide family exist in hemichordates and chordates but their relationship with PP/OK-type peptides has not been observed because of sequence divergence. Addressing this issue would be facilitated if the receptors that mediate the effects of PP/OK-type peptides in echinoderms or in protostomes were identified, and therefore this represents an important objective for future research on PP/OK-type peptides.

Acknowledgements and conflict of interest disclosure

This work was supported by Korea Ministry of Environment (MOE) as ‘Eco-innovation Program (201300030002)’, the China Scholarship Council (ML) and Queen Mary University of London (MRE). The authors declare that they have no conflicts of interest with the contents of this article.

All experiments were conducted in compliance with the ARRIVE guidelines.

Supporting information

Additional supporting information may be found in the online version of this article at the publisher’s web-site:

**Figure S1.** MALDI-TOF mass spectrum of purified peak A (A). Comparison of the chromatographic properties of synthetic SMP with a free carboxyl terminus (SMP) and SMP with an amidated carboxyl terminus (SMPamide) on RP-HPLC reveals that the two peptides elute at different retention times with isocratic 20% acetonitrile/0.1% TFA (B).

**Figure S2.** Precursor of starfish myorelaxant peptide (SMP)-type neuropeptides in Asterias rubens.

**Figure S3.** Multiple sequence alignment showing that starfish SMP precursors share sequence similarity with other echinoderm pedal peptide-type precursors (Sppn6, Sppn7, Attp7) and with protostomian pedal peptide (PP)/orcokinin(OK)-type peptide precursors.

**Table S1.** Primers used for RACE and RT-qPCR analysis of SMP precursor expression in P. Pectinifera.

**Table S2.** Identity and similarity grid showing the identity/similarity percentages for the amino acid sequences of SMP precursors and PP/OK-type peptide precursors.

**References**

Adoutte A., Balavoine G., Lartillot N., Lespinet O., Prud’homme B. and de Rosa R. (2000) The new animal phylogeny: reliability and implications. *Proc. Natl Acad. Sci. USA* 97, 4453–4456.

Bendena W. G., Garside C. S., Yu C. G. and Tobe S. S. (1997) Allatostatins: diversity in structure and function of an insect neuropeptide family. *Ann. N. Y. Acad. Sci.* 814, 53–66.

Blackburn M. B., Wagner R. M., Kochansky J. P., Harrison D. J., Thomas-Laemont P. and Raina A. K. (1995) The identification of two myoinhibitory peptides, with sequence similarities to the
galanins, isolated from the ventral nerve cord of *Manduca sexta*. *Regul. Pept.* 57, 213–219.

Brain S. D., Williams T. J., Tippins J. R., Morris H. R. and MacIntyre I. (1985) Calcitonin gene-related peptide is a potent vasodilator. *Nature* 313, 54–56.

Bungart D., Kegel G., Burdzik S. and Keller R. (1995) Structure-activity relationships of the crustacean myotropic neuropeptide okrin. *Peptides* 16, 199–204.

Conzelmann M., Offenburger S. L., Asadulina A., Keller T., Munch T. A. and Jekely G. (2011) Neuropeptides regulate swimming depth of *Platynereis larvae*. *Proc. Natl Acad. Sci. USA* 108, E1174–E1183.

Dan-Sohkawa M., Yamanaka H. and Watanabe K. (1986) A novel echinoderm neuropeptide with a potent relaxant effect on sea cucumber. *Holothuria glaberrima* (Echinodermata). *Comp. Biochem. Physiol. C* 110, 171–176.

Du H., Bao Z., Hou R. et al. (2012) Transcriptome sequencing and characterization for the sea cucumber *Apostichopus japonicus* (Selenka, 1867). *PLoS ONE* 7, e33311.

Elphick M. R. and Melarange R. (2001) Neural control of muscle relaxation in echinoderms. *J. Exp. Biol.* 204, 875–885.

Elphick M. R., Price D. A., Lee T. D. and Thorndyke M. C. (1991a) The isolation of the novel echinoderm neuropeptide SALMFamide-1 from starfish using a new antiserum. *Peptides* 12, 455–459.

Elphick M. R., Newman S. J. and Thorndyke M. C. (1995) Distribution and action of SALMFamide neuropeptides in the starfish *Asterias rubens*. *J. Exp. Biol.* 198, 2519–2525.

Elphick M. R., Achhala S. and Martyynuk N. (2013) The evolution and diversity of SALMFamide neuropeptides. *PLoS ONE* 8, e59076.

Elphick M. R., Semmens D. C., Blowes L. M., Levine J., Lowe C. J., Arnone M. I. and Clark M. S. (2015) Reconstructing SALMFamide neuropeptide precursor evolution in the phylum echinodermata: ophiurid and crinoid sequence data provide new insights. *Front. Endocrinol. (Lausanne)* 6, 2.

Greenberg M. J. and Price D. A. (1979) FMRFamide, a cardioexcitatory neuropeptide of molluscs: an agent in search of a mission. *Am. Zool.* 19, 163–174.

Grider J. R. and Mahlkolff G. M. (1986) Colonic peristaltic reflex: identification of vasoactive intestinal peptide as mediator of descending relaxation. *Am. J. Physiol.* 251, G40–G45.

Hall J. D. and Lloyd P. E. (1990) Involvement of peptide in locomotion in *Aplysia*: modulation of foot muscle contractions. *J. Neurobiol.* 21, 858–868.

Haraguchi S., Ikeda N., Abe M., Tsutsui K. and Mit a M. (2015) Nucleotide sequence and expression of relaxin-like gonad-stimulating peptide gene in starfish *Asterina pectinifera*. *Gen. Comp. Endocrinol.* pii: S0016-6480(15)00185-9. doi: 10.1016/j.ygece.2015.06.017. [Epub ahead of print].

Hauser H., Neupert S., Williamson M., Predel R., Tanaka Y. and Grimmellkhiizjifen C. J. (2010) Genomics and peptidomics of neuropeptides and protein hormones present in the parasitic wasp *Nasonia vitripennis*. *J. Proteome Res.* 9, 5296–5310.

Hofer S. and Homberg U. (2006) Evidence for a role of orcinolin-related peptides in the circadian clock controlling locomotor activity of the cockroach *Leucophaea maderae*. *J. Exp. Biol.* 209, 2794–2803.

Holman G. M., Cook B. J. and Nachman R. J. (1986) Isolation, primary structure and synthesis of leucysopressin, an insect neuropeptide that inhibits spontaneous contractions of the cockroach hindgut. *Comp. Biochem. Physiol. C* 85, 329–333.

Ikegami S., Tamura S. and Kanatani H. (1967) Starfish gonad: action and chemical identification of spawning inhibitor. *Science* 158, 1052–1053.

Jo Y. B., Park S. H., Jeon J. K., Ko C. H., Ryu C. and Park Y. K. (2013) Biodiesel production via the transesterification of soybean oil using waste starfish (Asterina pectinifera). *Appl. Biochem. Biotechnol.* 170, 1426–1436.

Kim C. H., Go H. J. and Park N. G. (2015) Two myomodulins isolated from central nervous system of Northwest Pacific Sea Hare, *Aplysia kurodai*, and their activities on other mollusks. *Protein Pept. Lett.* 22, 341–347.

Kitamura K., Kawagawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsu H. and Eto T. (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. *Biochem. Biophys. Res. Commun.* 192, 553–560.

Lloyd P. E. and Connolly C. M. (1989) Sequence of pedal peptide: a novel neuropeptide from the central nervous system of *Aplysia*. *J. Neurosci.* 9, 312–317.

Longley R. D. and Peterman M. (2013) Neuronal control of pedal sole cilia in the pond snail *Lymnaea stagnalis* appressa. *J. Comp. Physiol. A Neuroethol. Sens. Neural. Behav. Physiol.* 199, 71–86.

Melarange R. and Elphick M. R. (2003) Comparative analysis of nitric oxide and SALMFamide neuropeptides as general muscle relaxants in starfish. *J. Exp. Biol.* 206, 893–899.

Melarange R., Pottin D. J., Thorndyke M. C. and Elphick M. R. (1999) SALMFamide neuropeptides cause relaxation and evisceration of the cardiac stomach in *starfish*. *Proc. Biol. Sci. 266*, 1785–1785.

Mirabeau O. and Joly J. S. (2013) Molecular evolution of peptidergic signaling systems in bilaterians. *Proc. Natl Acad. Sci. USA* 110, E2028–E2037.

Mita M., Yoshikuni M., Ohno K., Shibata Y., Paul-Prasanth B., Pitchayawasin S., Isobe M. and Nagahama Y. (2009) A relaxin-like peptide purified from radial nerves induces oocyte maturation and ovulation in the starfish, *Asterina pectinifera*. *Proc. Natl Acad. Sci. USA* 106, 9507–9512.

Miyata A., Arimura A., Dahl R. R., Minamino N., Uehara A., Jiang L., Culler M. D. and Coy D. H. (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. *Biochem. Biophys. Res. Commun.* 164, 567–574.

Moore S. J. and Thorndyke M. C. (1993) Immunocytochemical mapping of the novel echinoderm neuropeptide SALMFamide 1 (S1) in the starfish *Asterias rubens*. *Cell Tissue Res.* 274, 605–618.

Moroz L. L., Edwards J. R., Puthanveettil S. V. et al. (2006) Neuronal transcriptome of *Aplysia*: neuronal compartments and circuitry. *Cell* 127, 1453–1467.

Nathoo A. N., Moellner R. A., Westlund B. A. and Hart A. C. (2001) Identification of neuropeptide-like protein gene families in *Caenorhabditis elegans* and other species. *Proc. Natl Acad. Sci. USA* 98, 14000–14005.

Newman S. J., Elphick M. R. and Thorndyke M. C. (1995a) Tissue distribution of the SALMFamide neuropeptide S2 and S2 in the starfish *Asterias rubens* using novel monoclonal and polyclonal antibodies. II. digestive system. *Proc. Biol. Sci.* 261, 187–192.

Newman S. J., Elphick M. R. and Thorndyke M. C. (1995b) Tissue distribution of the SALMFamide neuropeptides S1 and S2 in the starfish *Asterias rubens* using novel monoclonal and polyclonal antibodies. I. Nervous and locomotory systems. *Proc. Biol. Sci.* 261, 139–145.
Ohtani M., Iwakoshi E., Muneoka Y., Minakata H. and Nomoto K. (2002) Isolation and characterization of bioactive peptides from the sea cucumber, *Stichopus japonicus*, in *Peptide Science - Present and Future*, (Shimonishi Y., ed.), pp. 419–420. Springer, Netherlands.

Reich A., Dunn C., Akasaka K. and Wessel G. (2015) Phylogenomic analyses of Echinodermata support the sister groups of Asterozoa and Echinozoa. *PLoS ONE* **10**, e0119627.

Robberecht P., Tatemoto K., Chatelain P. *et al.* (1982) Effects of PHI on vasoactive intestinal peptide receptors and adenylate cyclase activity in lung membranes. A comparison in man, rat, mouse and guinea pig. *Regul. Pept.* **4**, 241–250.

Rowe M. L. and Elphick M. R. (2012) The neuropeptide transcriptome of a model echinoderm, the sea urchin *Strongylocentrotus purpuratus*. *Gen. Comp. Endocrinol.* **179**, 331–344.

Rowe M. L., Achhala S. and Elphick M. R. (2014) Neuropeptides and polypeptide hormones in echinoderms: new insights from analysis of the transcriptome of the sea cucumber *Apostichopus japonicus*. *Gen. Comp. Endocrinol.* **197**, 43–55.

Schilling L., Kanzler C., Schmiedek P. and Ehrenreich H. (1998) Characterization of the relaxant action of urocortin, a new peptide related to corticotropin-releasing factor in the rat isolated basilar artery. *Br. J. Pharmacol.* **125**, 1164–1171.

Semmens D. C., Dane R. E., Pancholi M. R., Slade S. E., Scrivens J. H. and Elphick M. R. (2013) Discovery of a novel neurophysin-associated neuropeptide that triggers cardiac stomach contraction and retraction in starfish. *J. Exp. Biol.* **216**, 4047–4053.

Soehler S., Stengl M. and Reischig T. (2011) Circadian pacemaker coupling by multi-peptidergic neurons in the cockroach *Leucophaga maderae*. *Cell Tissue Res.* **343**, 559–577.

Stangier J., Hilbich C., Burdzik S. and Keller R. (1992) Orcokinin: a novel myotropic peptide from the nervous system of the crayfish, *Orconectes limosus*. *Peptides* **13**, 859–864.

Wei H. and Stengl M. (2011) Light affects the branching pattern of peptidergic circadian pacemaker neurons in the brain of the cockroach *Leucophaga maderae*. *J. Biol. Rhythms* **26**, 507–517.

Williams C. L., Peterson J. M., Villar R. G. and Burks T. F. (1987) Corticotropin-releasing factor directly mediates colonic responses to stress. *Am. J. Physiol.* **253**, G582–G586.

Yamanaka N., Roller L., Zitnan D., Satake H., Mizoguchi A., Kataoka H. and Tanaka Y. (2011) Bombyx orcokinins are brain-gut peptides involved in the neuronal regulation of ecdysteroidogenesis. *J. Comp. Neurol.* **519**, 238–246.

Yasuda-Kamatani Y. and Yasuda A. (2000) Identification of orcokinin gene-related peptides in the brain of the crayfish *Procambarus clarkii* by the combination of MALDI-TOF and on-line capillary HPLC/Q-Tof mass spectrometries and molecular cloning. *Gen. Comp. Endocrinol.* **118**, 161–172.